Tuesday, February 17, 2026

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

›
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to trea...
Monday, February 16, 2026

FDA Approves Caplyta (lumateperone) as an Adjunctive Therapy for the Treatment of Major Depressive Disorder (MDD) in Adults

›
In continuation of my update on lumateperone Johnson & Johnson (NYSE: JNJ) announced the U.S. Food and Drug Administration (FDA) approva...
Friday, February 13, 2026

FDA Approves Zoryve for Atopic Dermatitis in Young Children

›
In continuation of my update on Zoryve The U.S. Food and Drug Administration has approved the supplemental new drug application for Zoryve (...
Thursday, February 12, 2026

Niraparib Plus AAP Improves Survival in mCSPC With HRR Gene Alterations

›
In continuation of my update on Niraparib For patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombin...
Wednesday, February 11, 2026

Tramadol May Have Slight Effect on Reducing Chronic Pain

›
In continuation of my update on Tramadol.. Tramadol may slightly reduce chronic pain but seems to increase the risk for serious and nonserio...
Tuesday, February 10, 2026

High Flavanol Consumption May Counteract Sitting-Induced Endothelial Dysfunction

›
In continuation of my update on Flavanol Consuming high-flavanol foods and drinks may reduce some of the impact of prolonged sitting on the ...
Monday, February 9, 2026

Intranasal Insulin, Empagliflozin Have Promising Effects on Cognition

›
In continuation of my update Empagliflozan Intranasal insulin (INI) and empagliflozin are safe and have promising effects on cognition, acco...
Friday, February 6, 2026

AHA: Low-Dose Aspirin Use Linked to Lower ASCVD Outcomes in Type 2 Diabetes

›
In continuation of my update on aspirin For adults with type 2 diabetes, low-dose aspirin (ASA) use is associated with a lower risk for myo...
Thursday, February 5, 2026

Pazopanib Well-Tolerated in Young With Primary Multimetastatic Ewing Sarcoma

›
In continuation of my update on  Pazopanib For young patients with primary multimetastatic Ewing sarcoma, pazopanib is well-tolerated and ef...
Wednesday, February 4, 2026

Existing drug, Ulipristal acetate- could reduce breast cancer risk in pre-menopausal women

›
In continuation of my update on Ulipristat NYU Langone Health researchers found that a type of cell death caused by a buildup of highly reac...
Tuesday, February 3, 2026

FDA Issues Complete Response Letter for Biohaven's Vyglxia (troriluzole) New Drug Application for Spinocerebellar Ataxia

›
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development a...
Monday, February 2, 2026

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

›
In continuation of my update on  ibrutinib Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere...
Saturday, January 31, 2026

FDA Approves Kygevvi (doxecitine and doxribtimine) for the Treatment of Thymidine Kinase 2 Deficiency

›
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that Kygevvi has been granted approval by the U.S. Food an...
Friday, January 30, 2026

FDA Approves Epioxa (riboflavin 5’-phosphate) Ophthalmic Solution for the Treatment of Keratoconus

›
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, c...
Thursday, January 29, 2026

FDA Approves Contepo (fosfomycin) for Injection for the Treatment of Complicated Urinary Tract Infections

›
In Continuation of my update on fosfomycin The U.S. Food and Drug Administration (FDA) has approved Contepo (fosfomycin) for injection for t...